Torrent Pharmaceuticals files BRSR for FY26
Torrent Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with the stock exchanges, complying with SEBI regulations. The report details a standalone turnover of ₹10,498 crore, a workforce of 20,341, and the completion of its first Double Materiality Assessment. Key initiatives include energy conservation projects, a 54% reduction in hazardous waste, and the implementation of Zero Liquid Discharge mechanisms.
*this image is generated using AI for illustrative purposes only.
Torrent Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with BSE Limited and the National Stock Exchange of India Limited. The filing, submitted on June 1, 2026, complies with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report includes an Independent Reasonable and Limited Assurance Report issued by Grant Thornton Bharat LLP and forms part of the company's Integrated Annual Report for FY 2025-26.
Company Overview and Key Financial Parameters
Torrent Pharmaceuticals, incorporated in 1972 and headquartered in Ahmedabad, reported a standalone turnover of ₹10,498 crore and a net worth of ₹8,452 crore as on March 31, 2026. The company's paid-up capital stands at ₹169.23 crore. Pharmaceutical products account for 100% of its turnover. The company operates 9 national plants, including an R&D unit, and 30 national offices, serving more than 50 international markets through 17 offices.
| Parameter: | Details |
|---|---|
| CIN: | L24230GJ1972PLC002126 |
| Paid-up Capital: | ₹169.23 crore (as on 31st March, 2026) |
| Standalone Turnover: | ₹10,498 crore |
| Net Worth: | ₹8,452 crore |
| Export Contribution (Standalone): | 28% of total turnover |
| Export Contribution (Consolidated): | 41% of total turnover |
| National Plants: | 9 (includes R&D unit) |
| National Offices: | 30 |
| International Offices: | 17 |
| International Markets Served: | More than 50 |
| Assurance Provider: | Grant Thornton Bharat LLP |
Workforce and Inclusion Metrics
As at the end of FY 2025-26, the company employed a total of 16,735 employees and 3,606 workers. The workforce composition reflects a predominantly male workforce, with women representing 8% of total employees and 14% of total workers. The Board of Directors comprises 7 members, of whom 2 (29%) are women. Key Managerial Personnel number 4, with no female representation.
| Category: | Total | Male | Female |
|---|---|---|---|
| Permanent Employees: | 16,499 | 15,150 (92%) | 1,349 (8%) |
| Other than Permanent Employees: | 236 | 220 (93%) | 16 (7%) |
| Total Employees: | 16,735 | 15,370 (92%) | 1,365 (8%) |
| Permanent Workers: | 529 | 504 (95%) | 25 (5%) |
| Other than Permanent Workers: | 3,077 | 2,601 (85%) | 476 (15%) |
| Total Workers: | 3,606 | 3,105 (86%) | 501 (14%) |
| Differently Abled Employees: | 23 | 19 (83%) | 4 (17%) |
| Differently Abled Workers: | 15 | 14 (93%) | 1 (7%) |
ESG Strategy and Double Materiality Assessment
In FY 2025-26, Torrent Pharmaceuticals conducted its first Double Materiality Assessment (DMA), guided by the European Sustainability Reporting Standards (ESRS). The assessment identified material sustainability topics such as Climate Change Adaptation and Mitigation, Resource Management, and Occupational Health & Safety, classifying them by risk or opportunity and financial implication. The Corporate Social Responsibility and Sustainability Committee of the Board oversees sustainability strategy implementation.
Environmental Stewardship and Energy Initiatives
Torrent Pharmaceuticals implemented multiple energy efficiency initiatives in FY 2025-26, including the replacement of chillers at the Indrad facility, saving 77,000 KWH per annum, and the installation of demand-based control for chillers at Dahej, saving 4,40,000 KWH per annum. The company reported a 54% reduction in hazardous waste generation from the base year FY20. A group captive 6.6 MW and 3.3 MW hybrid plant has been approved for installation by FY27. The company has implemented Zero Liquid Discharge (ZLD) mechanisms at its manufacturing facilities and R&D Centre.
Governance, Compliance, and Consumer Responsibility
The company's governance framework includes policies on Business Conduct, Whistle-Blower, Related Party Transactions, and Materiality of Events. During FY 2025-26, no complaints were received related to human rights issues, and no instances of data breaches were reported. The company recorded 3 voluntary product recalls on account of quality issues and 1 forced recall initiated by a regulatory authority. R&D investment as a percentage of total R&D spend stood at 4.62% for FY 2025-26, while Capex investment in environment and social impact technologies stood at 4.63%.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE685A01028/9276652ea0524aad.pdf
Historical Stock Returns for Torrent Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.17% | -1.88% | +4.38% | +17.18% | +39.67% | +212.59% |
How will the implementation of the new 6.6 MW and 3.3 MW hybrid captive power plant impact Torrent Pharmaceuticals' operational costs and carbon footprint by FY27?
What specific targets has Torrent set following its first Double Materiality Assessment to address the identified risks in Climate Change Adaptation and Resource Management?
Given the low female representation in Key Managerial Personnel, what strategic initiatives is the company planning to improve gender diversity in senior leadership roles?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
